Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

References

• IDF. Diabetes atlas ninth edition; 2019. Available from: www.diabetesatlas.org.
   Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85. doi:10.2337/dc18-S008
   PubMed Web of Science ®Google Scholar
• Wang YW, He SJ, Feng X, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017;11:2421–2429. doi:10.2147/DDDT.S141675
   PubMed Web of Science ®Google Scholar
• Metformin hydrochloride - drug usage statistics. ClinCalc; 2019. Accessed April 7, 2020.
   Google Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98. doi:10.2165/11534750-000000000-00000
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–966. doi:10.1016/j.cmet.2014.09.018
   PubMed Web of Science ®Google Scholar
• Graham Rena D, Hardie G, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z
   PubMedGoogle Scholar
• Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017;60(9):1630–1638. doi:10.1007/s00125-017-4349-5
   PubMed Web of Science ®Google Scholar
• Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–2351. doi:10.2337/diacare.28.10.2345
   PubMed Web of Science ®Google Scholar
• Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006;166(18):1975–1979. doi:10.1001/archinte.166.18.1975
   PubMedGoogle Scholar
• U.S. Department of Agriculture. Agricultural Research Service. FoodData Central; 2019.
   Google Scholar
• Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998.
   Google Scholar
• Banerjee R, Ragsdale SW. The many faces of vitamin B 12: catalysis by cobalamin-dependent enzymes. Annu Rev Biochem. 2003;72(1):209–247. doi:10.1146/annurev.biochem.72.121801.161828
   PubMedGoogle Scholar
• Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician. 2009;79(3):203–208.
   PubMedGoogle Scholar
• Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101:1754‒1761.
   PubMedGoogle Scholar
• Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J. 2010;103(3):265–267. doi:10.1097/SMJ.0b013e3181ce0e4d
   PubMed Web of Science ®Google Scholar
• Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008;112(6):2214–2221. doi:10.1182/blood-2008-03-040253
   PubMed Web of Science ®Google Scholar
• Filioussi K, Bonvoas S, Katsaros T. Should we screen diabetes patients using biguanides for megaloblastic anaemia? Aust Fam Physician. 2003;32(5):383‒384.
   PubMedGoogle Scholar
• Callaghan TS, Hadden DR, Tomkin GH. Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. Br Med J. 1980;280(6225):1214‒1215. doi:10.1136/bmj.280.6225.1214
   PubMedGoogle Scholar
• Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35(2):200‒201. doi:10.1093/ageing/afj042
   Google Scholar
• Fujita H, Narita T, Yoshioka N, et al. A case of megaloblastic anemia due to vitamin B12 deficiency precipitated in a totally gastrectomized type II diabetic patient following the introduction of metformin therapy. Endocr J. 2003;50(4):483‒484. doi:10.1507/endocrj.50.483
   Google Scholar
• Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–575. doi:10.1001/jama.291.5.565
   PubMed Web of Science ®Google Scholar
• McKay DL, Perrone G, Rasmussen H, Dallal G, Blumberg JB. Multivitamin/mineral supplementation improves plasma B-vitamin status and homocysteine concentration in healthy older adults consuming a folate-fortified diet. J Nutr. 2000;130(12):3090–3096. doi:10.1093/jn/130.12.3090
   PubMedGoogle Scholar
• Gustavo Saposnik JG, Ray PS, McQueen M, McQueen M, Lonn E. The HOPE 2 investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability. Stroke. 2009;40(4):1365–1372. doi:10.1161/STROKEAHA.108.529503
   PubMedGoogle Scholar
• Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795–804. doi:10.1001/jama.300.7.795
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT trial investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–1588. doi:10.1056/NEJMoa055227
   PubMed Web of Science ®Google Scholar
• Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke. 2005;36(11):2404–2409. doi:10.1161/01.STR.0000185929.38534.f3
   PubMed Web of Science ®Google Scholar